In this study, we revealed that pOVA vaccines, in combination with α-PD-1 expressed by pVAX-α-PD-1, can trigger tumor death in a CD8+ T cell-dependent manner, and that treatment with α-PD-1 antibody alone moderately inhibited tumor growth. The gene discussed is RPL17; the disease is neoplasm.